Cogstate Limited (ASX:CGS) has signed a series of contracts worth US$4.9 million with a large international pharmaceutical company for the use of its computerised cognitive tests for a Phase III depression clinical trial program.
This takes the total value of contracts signed in the financial year to date to US$21.9 million, a record.
This is 143.3% improvement on the US$9 million of sales contracts for the previous year.
The growth in the clinical trials business is a result of changes made within the business to enhance business development activities and operational delivery.
Cogstate has increased business development resources for the Clinical Trials business.
Significantly, it has evolved its business model from a scientist based peer-to-peer selling model to a formalised commercial business development team, leading to better identification and conversion of sales opportunities.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.72 |
Change
-0.020(1.15%) |
Mkt cap ! $292.0M | |||
| Open | High | Low | Value | Volume |
| $1.75 | $1.76 | $1.70 | $92.54K | 53.51K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7005 | $1.71 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.74 | 158428 | 1 |
View Market Depth
| Last trade - 16.10pm 15/07/2025 (20 minute delay) ? |
| CGS (ASX) Chart |